Patient Support Programme Emails: Improving Adherence and Outcomes Through Email

Medication adherence is one of the most significant challenges in modern healthcare. Studies consistently show that 50% or more of patients with chronic conditions do not take their medication as prescribed — a failure that costs healthcare systems billions and, in many disease areas, directly impacts patient outcomes.

For pharmaceutical companies, the commercial implications are equally stark. Non-adherent patients refill less frequently, discontinue therapy earlier, and generate lower lifetime value from a brand investment in their condition. A 10% improvement in adherence for a chronic therapy drug is not a soft wellbeing metric — it translates directly to prescription volume.

Patient support programme (PSP) emails are among the most cost-effective tools pharmaceutical brands have for improving both outcomes and commercial performance. This guide is for the brand or medical affairs lead responsible for making that programme work.

The Business Case for Patient Support Emails

The case for investing in PSP email infrastructure is strong. Research across multiple therapeutic areas shows that patients enrolled in support programmes demonstrate meaningfully higher adherence rates than those who are not — with some studies showing 15-30% improvement in persistence at 12 months.

The commercial impact of this improvement compounds over time. A patient who stays on therapy for 18 months instead of 11 generates 64% more prescription revenue from the same acquisition cost. When you factor in the cost of PSP email infrastructure — which, once built, operates at near-zero marginal cost per patient — the ROI is compelling even in relatively low-volume programmes.

Beyond adherence, PSP emails generate a quality of brand relationship that promotional communications cannot. A patient who receives genuinely helpful information about managing their condition, understanding their therapy, and accessing support resources develops trust in the brand that extends through therapy changes, generic competition, and patient advocacy.

Programme Enrolment Flows

The gateway to all PSP email benefits is enrolment. Patients need to understand what the programme offers, actively choose to participate, and complete whatever consent process your regulatory and legal teams require.

The most effective enrolment flows use multiple touchpoints: an initial invitation delivered through the prescribing HCP (whether digitally via the rep or physically via patient pack insert), followed by a direct-to-patient email if contact details have been captured, with a simple one-click or form-based enrolment mechanism.

The enrolment email itself should answer three questions immediately: what is this programme, what will I receive, and what does it ask of me? The answer to the third question should be “nothing” — PSP enrolment should be frictionless, with opt-down options for patients who want fewer touchpoints rather than complete re-enrolment required to adjust preferences.

A common failure mode in PSP enrolment is over-promising in the initial communication. If a patient enrols expecting daily support and receives a monthly newsletter, churn from the programme will be high. Set accurate expectations and then exceed them.

Adherence Reminder Sequences: The Critical First 90 Days

The highest-risk period for therapy discontinuation is the first 90 days. Patients who are new to a therapy face the combined challenges of establishing a new routine, managing initial side effects, and sustaining motivation before the treatment’s benefits are fully apparent.

An adherence reminder sequence designed for this window should not instruct patients when or how to take their medication — that is clinical instruction and sits outside what a PSP email programme can appropriately deliver. What it can do is:

Acknowledge the adjustment period. Emails that validate the experience of starting a new therapy (“the first few weeks can feel different — here is what many patients tell us about that adjustment period”) build rapport and reduce anxiety-driven discontinuation.

Connect patients to support resources. Prominently surfacing the nurse helpline number, patient community, or pharmacist consultation service at moments when patients are likely to have questions — particularly around week 2-3 when initial side effects often emerge — reduces unanswered questions that turn into discontinuation decisions.

Reinforce the clinical rationale. Without crossing into clinical instruction, reminder emails can reinforce why consistency matters in a particular therapy area. For a patient starting a biologic for an inflammatory condition, understanding that the drug builds effect over time makes the early weeks more bearable.

Side Effect Education Emails

Unmanaged side effects are among the leading reasons patients discontinue therapy prematurely. Many of these discontinuations are preventable — not because the side effects can be eliminated, but because patients who understand and expect them are far more likely to manage through them.

A side effect education sequence, deployed in the first 2-4 weeks of therapy when common side effects are most likely to emerge, should be developed with your medical affairs team and subject to careful copy review. The goal is to prepare, not alarm.

Effective side effect education emails describe what patients might notice, frame it accurately (common but typically manageable vs rare but serious), explain what actions are appropriate (self-management strategies, when to consult their pharmacist or doctor), and reinforce that the support programme is available if they have concerns.

The outcome data on proactive side effect education is consistent: patients who receive this communication discontinue therapy at lower rates than matched patients who do not. The mechanism is straightforward — uncertainty and fear are reduced when they are anticipated and addressed rather than encountered as surprises.

Co-Pay and Financial Support Communication

In markets where patient out-of-pocket costs are significant — particularly the United States — financial barriers to adherence are real. Patients who cannot afford their co-pay do not refill their prescription.

Co-pay assistance programme emails are therefore one of the highest direct-impact PSP communications available. An email that clearly explains the co-pay assistance programme, who qualifies, how to enrol, and what savings are available has an immediate and measurable impact on refill behaviour.

These emails should be sent proactively at enrolment, triggered by refill timing windows, and re-sent when assistance programme terms change or improve. Patients who qualified and did not enrol in the co-pay programme when they started therapy are a high-priority re-engagement segment.

Nurse or Support Line Email Touchpoints

Many pharmaceutical PSPs include access to a specialist nurse helpline or patient support coach. The effectiveness of these programmes depends entirely on whether patients use them — which in turn depends on whether they know the service exists and feel comfortable reaching out.

Email plays a critical role in keeping the support line front of mind throughout the patient journey. Touchpoints that work particularly well:

Introduction emails at the start of therapy that humanise the support team (a named nurse or coordinator, a brief description of what they help with, the channel preferences available — phone, email, webchat).

Milestone emails at key therapy points (one month, three months, six months) that check in and resurface the support line as a resource.

Triggered support offers when a patient’s engagement with the programme drops — a signal that may indicate they are struggling with therapy.

The key principle is that support line emails should feel like genuine care communication, not marketing. The moment they feel promotional, they lose the trust that makes them valuable.

HIPAA Compliance in Patient Email Programmes

In the United States, patient email programmes that involve Protected Health Information (PHI) — which includes individual health conditions, treatment information, or any data that could identify a person in connection with their health — fall within HIPAA scope.

HIPAA compliance for patient email programmes requires a Business Associate Agreement (BAA) with your email service provider, confirmed technical safeguards for PHI in email transmission and storage, and careful attention to what information appears in email subject lines and preview text.

Many pharmaceutical PSP email programmes navigate HIPAA requirements by structuring their programmes so that the ESP handles only non-PHI data (name, email address, generic programme preference signals), with condition-specific or treatment-specific personalisation handled through a compliant healthcare CRM system that manages the PHI elements.

Regardless of approach, HIPAA compliance review by your legal team is a prerequisite, not an optional step.

Measuring Programme Success

PSP email programme metrics should be structured around the outcomes the programme exists to deliver, not just standard email marketing KPIs.

Adherence metrics — refill rates, days on therapy, programme-enroled vs non-enroled therapy persistence — are the primary success measures. Establishing baseline adherence data before programme launch enables genuine pre-post measurement.

Engagement metrics — email open rate, support line call rate, resource download rate — are leading indicators that predict adherence outcomes and allow you to optimise the programme before the adherence data matures.

Net Promoter Score or satisfaction measurement within the PSP enrolment base provides a qualitative layer that helps identify which programme elements are generating the most value and which need refinement.

Related Excelohunt Services

• Email Automations — Patient support programme sequences built around therapeutic milestones, adherence windows, and behaviour triggers.
• Email Strategy — PSP email programme architecture from enrolment flow design to measurement framework and compliance review integration.
• Email Campaigns — Campaign-based PSP communications for programme launches, seasonal health moments, and adherence intervention periods.

Get a free email audit for your brand →